共 185 条
[1]
Kuchenbaecker KB(2017)Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers JAMA 317 2402-414
[2]
Hopper JL(2012)The role of BRCA1 and BRCA2 in prostate cancer Asian J Androl 14 409-59
[3]
Barnes DR(2011)Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine CA Cancer J Clin. 61 327-4185
[4]
Phillips KA(2016)Population Frequency of Germline BRCA1/2 Mutations J Clin Oncol Off J Am Soc Clin Oncol 34 4183-259
[5]
Mooij TM(2005)Genetic Risk Assessment and Ann Intern Med. 143 362-27
[6]
Roos-Blom MJ(2020) Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the US Preventive Services Task Force Breast Care 15 253-134
[7]
Castro E(2016)Factors Impacting on Decision-Making towards Prophylactic Surgeries in BRCA Mutation Carriers and Women with Familial Predisposition Soc Sci Med 1 21-128S
[8]
Eeles R(2013)“It’s not if I get cancer, it’s when I get cancer”: BRCA-positive patients’ (un)certain health experiences regarding hereditary breast and ovarian cancer risk Psychol Health Med 18 125-391
[9]
Weitzel JN(2013)Living with the BRCA genetic mutation: An uncertain conclusion to an unending process Med Care Res Rev. 70 113S-569
[10]
Blazer KR(2004)Supporting Shared Decisions When Clinical Evidence Is Low Psychol Bull 130 355-16